{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:11Z","timestamp":1786998371288,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ygyno.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T18:01:06Z","timestamp":1682445666000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients"],"prefix":"10.1016","volume":"173","author":[{"given":"Thibault","family":"Gauduchon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kfoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Salaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Rivoirard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Favier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Berton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"de la Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Abdeddaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Prulhiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lancry Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Provansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Dalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2023.04.002_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2023.04.002_bb0010","first-page":"284","article-title":"Ovarian Cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"7353","key":"10.1016\/j.ygyno.2023.04.002_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2023.04.002_bb0020","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"01;29","author":"Ledermann","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2023.04.002_bb0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.002_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2023.04.002_bb0035","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"25","key":"10.1016\/j.ygyno.2023.04.002_bb0040","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2023.04.002_bb0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2023.04.002_bb0050","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2023.04.002_bb0055","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2023.04.002_bb0060","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.ygyno.2023.04.002_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102040","article-title":"Incorporating Parp-inhibitors in primary and recurrent ovarian Cancer: a Meta-analysis of 12 phase II\/III randomized controlled trials","volume":"87","author":"Ruscito","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.04.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"Du Bois","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.04.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.6001","article-title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2","volume":"38","author":"Zang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"148","key":"10.1016\/j.ygyno.2023.04.002_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"1","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ygyno.2023.04.002_bb0085","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1200\/EDBK_238755","article-title":"Wanna get away? Maintenance treatments and chemotherapy holidays in gynecologic cancers","volume":"39","author":"Madariaga","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet."},{"issue":"8","key":"10.1016\/j.ygyno.2023.04.002_bb0090","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.04.002_bb0095","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21873\/anticanres.15681","article-title":"Response to chemotherapy and clinical outcome of patients with recurrent epithelial ovarian Cancer after PARP inhibitor maintenance treatment: a multicenter retrospective Italian study","volume":"42","author":"Gadducci","year":"2022","journal-title":"Anticancer Res."},{"issue":"22","key":"10.1016\/j.ygyno.2023.04.002_bb0100","first-page":"01740","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"S0923-7534","author":"Frenel","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.002_bb0105","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in Oligometastatic ovarian Cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ygyno.2023.04.002_bb0110","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/IGC.0000000000000939","article-title":"Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian Cancer: a single-center initial experience","volume":"27","author":"Liu","year":"2017","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"issue":"5","key":"10.1016\/j.ygyno.2023.04.002_bb0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jvir.2021.01.270","article-title":"Image-guided percutaneous thermal ablation of Oligometastatic ovarian and non-ovarian gynecologic tumors","volume":"32","author":"Yuan","year":"2021","journal-title":"J. Vasc. Interv. Radiol. JVIR."},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.002_bb0120","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European organisation for research and treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.002_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2014.12.003","article-title":"Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases","volume":"114","author":"Fode","year":"2015","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.04.002_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pros.22750","article-title":"Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer","volume":"74","author":"Ost","year":"2014","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.ygyno.2023.04.002_bb0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2023.04.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101131","article-title":"Genetic regressive trajectories in colorectal cancer: a new hallmark of oligo-metastatic disease?","volume":"14","author":"Ottaiano","year":"2021","journal-title":"Transl. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2023.04.002_bb0145","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2005.05.3439","article-title":"Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors","volume":"24","author":"Raut","year":"2006","journal-title":"J. Clin. Oncol. of. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.04.002_bb0150","article-title":"Stereotactic ablative radiation therapy for Oligoprogressive renal cell carcinoma","volume":"6","author":"Schoenhals","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.04.002_bb0155","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/jca.26494","article-title":"First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease","volume":"10","author":"Xu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2023.04.002_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer."},{"issue":"(16_suppl","key":"10.1016\/j.ygyno.2023.04.002_bb0165","article-title":"OReO\/ENGOT Ov-38 trial: impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis\u2014an exploratory joint analysis of the BRCA and non-BRCA cohorts","volume":"40","author":"Selle","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823001737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823001737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:05:24Z","timestamp":1758773124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823001737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"alternative-id":["S0090825823001737"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}